Development of Side Effects From Betaxolol Clinical Trial
Official title:
Topical Betaxolol for the Prevention of Retinopathy of Prematurity
We hypothesize that topical betaxolol will reduce the development of severe retinopathy of prematurity.
The drug is administered twice a day between 32 and 35 weeks gestational age, at a t ime when ROP is most likely to arise. ;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention